Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.

Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx065.

2.

HER2 missense mutations have distinct effects on oncogenic signaling and migration.

Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, Erlanger B, Parsons HA, Manto KM, Bose R, Lauring J, Arteaga CL, Konstantopoulos K, Park BH.

Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6205-14. doi: 10.1073/pnas.1516853112. Epub 2015 Oct 27.

3.

EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.

Gallant JN, Sheehan JH, Shaver TM, Bailey M, Lipson D, Chandramohan R, Red Brewer M, York SJ, Kris MG, Pietenpol JA, Ladanyi M, Miller VA, Ali SM, Meiler J, Lovly CM.

Cancer Discov. 2015 Nov;5(11):1155-63. doi: 10.1158/2159-8290.CD-15-0654. Epub 2015 Aug 18.

4.

LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.

Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, González-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CL.

J Clin Invest. 2014 Dec;124(12):5490-502. doi: 10.1172/JCI72573. Epub 2014 Nov 17.

5.

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.

Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W.

Nat Med. 2014 Sep;20(9):1027-34. doi: 10.1038/nm.3667. Epub 2014 Aug 31.

6.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W.

Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.

7.

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer.

Red Brewer M, Yun CH, Lai D, Lemmon MA, Eck MJ, Pao W.

Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):E3595-604. doi: 10.1073/pnas.1220050110. Epub 2013 Sep 9. Erratum in: Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20344.

8.

Maximizing the benefits of off-target kinase inhibitor activity.

Red Brewer M, Pao W.

Cancer Discov. 2013 Feb;3(2):138-40. doi: 10.1158/2159-8290.CD-12-0581.

9.

The juxtamembrane region of the EGF receptor functions as an activation domain.

Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, Lemmon MA, Carpenter G.

Mol Cell. 2009 Jun 26;34(6):641-51. doi: 10.1016/j.molcel.2009.04.034.

10.

EpCAM: another surface-to-nucleus missile.

Carpenter G, Red Brewer M.

Cancer Cell. 2009 Mar 3;15(3):165-6. doi: 10.1016/j.ccr.2009.02.005. Review.

11.

Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor.

Whitson KB, Whitson SR, Red-Brewer ML, McCoy AJ, Vitali AA, Walker F, Johns TG, Beth AH, Staros JV.

Biochemistry. 2005 Nov 15;44(45):14920-31.

PMID:
16274239

Supplemental Content

Loading ...
Support Center